MA60976B1 - Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine - Google Patents
Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamineInfo
- Publication number
- MA60976B1 MA60976B1 MA60976A MA60976A MA60976B1 MA 60976 B1 MA60976 B1 MA 60976B1 MA 60976 A MA60976 A MA 60976A MA 60976 A MA60976 A MA 60976A MA 60976 B1 MA60976 B1 MA 60976B1
- Authority
- MA
- Morocco
- Prior art keywords
- ethan
- phenyl
- positive allosteric
- allosteric modulators
- dihydroisoquinoleine
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 102000004076 Dopamine D1 Receptors Human genes 0.000 title 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 title 1
- -1 (phenyl)-3,4-dihydroisoquinolin-2(1h)-yl Chemical group 0.000 abstract 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical class CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne certains composés (phényle)-3,4-dihydroisoquinolin-2(1h)-yl)ethan-1-one de formule i en tant que modulateurs allostériques positifs (pam) de d1, et des compositions pharmaceutiques de ceux-ci. L'invention concerne également des méthodes d'utilisation d'un composé de formule i, pour traiter certains symptômes de troubles dopaminergiques du snc, notamment la maladie de parkinson, la schizophrénie, le tdah ou la maladie d'alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063088479P | 2020-10-07 | 2020-10-07 | |
| PCT/US2021/053578 WO2022076418A1 (fr) | 2020-10-07 | 2021-10-05 | Dérivés de phényl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one en tant que modulateurs allostériques positifs du récepteur d1 de la dopamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA60976B1 true MA60976B1 (fr) | 2024-05-31 |
Family
ID=78516911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA60976A MA60976B1 (fr) | 2020-10-07 | 2021-10-05 | Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230382869A1 (fr) |
| EP (1) | EP4200280B1 (fr) |
| JP (1) | JP2023545060A (fr) |
| CN (1) | CN116601146A (fr) |
| DK (1) | DK4200280T3 (fr) |
| ES (1) | ES2976784T3 (fr) |
| FI (1) | FI4200280T3 (fr) |
| HR (1) | HRP20240466T1 (fr) |
| HU (1) | HUE066426T2 (fr) |
| LT (1) | LT4200280T (fr) |
| MA (1) | MA60976B1 (fr) |
| MD (1) | MD4200280T2 (fr) |
| PL (1) | PL4200280T3 (fr) |
| PT (1) | PT4200280T (fr) |
| RS (1) | RS65365B1 (fr) |
| SI (1) | SI4200280T1 (fr) |
| WO (1) | WO2022076418A1 (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| CN107001278B (zh) * | 2014-10-08 | 2020-11-24 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
-
2021
- 2021-10-05 JP JP2023521348A patent/JP2023545060A/ja active Pending
- 2021-10-05 EP EP21802476.8A patent/EP4200280B1/fr active Active
- 2021-10-05 WO PCT/US2021/053578 patent/WO2022076418A1/fr active Application Filing
- 2021-10-05 RS RS20240398A patent/RS65365B1/sr unknown
- 2021-10-05 FI FIEP21802476.8T patent/FI4200280T3/fi active
- 2021-10-05 ES ES21802476T patent/ES2976784T3/es active Active
- 2021-10-05 HU HUE21802476A patent/HUE066426T2/hu unknown
- 2021-10-05 MD MDE20230653T patent/MD4200280T2/ro unknown
- 2021-10-05 SI SI202130120T patent/SI4200280T1/sl unknown
- 2021-10-05 LT LTEPPCT/US2021/053578T patent/LT4200280T/lt unknown
- 2021-10-05 PL PL21802476.8T patent/PL4200280T3/pl unknown
- 2021-10-05 MA MA60976A patent/MA60976B1/fr unknown
- 2021-10-05 US US18/030,853 patent/US20230382869A1/en active Pending
- 2021-10-05 PT PT218024768T patent/PT4200280T/pt unknown
- 2021-10-05 DK DK21802476.8T patent/DK4200280T3/da active
- 2021-10-05 CN CN202180077762.XA patent/CN116601146A/zh active Pending
- 2021-10-05 HR HRP20240466TT patent/HRP20240466T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK4200280T3 (da) | 2024-03-04 |
| US20230382869A1 (en) | 2023-11-30 |
| HUE066426T2 (hu) | 2024-08-28 |
| EP4200280B1 (fr) | 2024-02-21 |
| MD4200280T2 (ro) | 2024-08-31 |
| FI4200280T3 (fi) | 2024-05-03 |
| PT4200280T (pt) | 2024-03-26 |
| CN116601146A (zh) | 2023-08-15 |
| PL4200280T3 (pl) | 2024-05-20 |
| WO2022076418A1 (fr) | 2022-04-14 |
| JP2023545060A (ja) | 2023-10-26 |
| LT4200280T (lt) | 2024-04-25 |
| HRP20240466T1 (hr) | 2024-07-05 |
| RS65365B1 (sr) | 2024-04-30 |
| EP4200280A1 (fr) | 2023-06-28 |
| SI4200280T1 (sl) | 2024-04-30 |
| ES2976784T3 (es) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43756B1 (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| MA30289B1 (fr) | Dérivés d'amines | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA42442B1 (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| MA27840A1 (fr) | Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2 | |
| MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
| MA33552B1 (fr) | Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques | |
| MA46101B1 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA31447B1 (fr) | Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
| MA31087B1 (fr) | Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde. | |
| MA29685B1 (fr) | Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques | |
| MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| MA30784B1 (fr) | Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs. | |
| TN2009000112A1 (fr) | Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques | |
| TN2009000028A1 (fr) | Agonistes de ep2 | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA27692A1 (fr) | Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments | |
| MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA46342A (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation |